Stephen Naylor's Biography

Stephen Naylor, Chairman & CEO, MaiHealth Inc & ReNeuroGen LLC

Dr Stephen Naylor PhD is currently the CEO and Co-founder of ReNeuroGen, a spin-out company from the Medical College of Wisconsin as well as the Founder, CEO and Chairman of MaiHealth Inc., a precision medicine/molecular systems bioprofile diagnostics company in the health and wellness sector. He is the former Founder, Chairman and CEO of Predictive Physiology and Medicine Inc. (2004-2010). This was one of the world’s first personalized medicine companies offering a series of information content tools to consumers. This Company was acquired by a privately held health education and literacy company in September 2010. He is also the former Chief Technology Officer (CTO), and Senior Vice President for Research at Beyond Genomics (2000-2003), a Systems Biology company based in Waltham, MA, where in concert with his colleagues, he built the world’s first integrated systems biology platform, consisting of analytical, bioinformatic and knowledge assembly capability. The Company subsequently changed its name to BG Medicine, and successfully executed an IPO in February 2011, and is now traded on the NASDAQ as BGMD. He has over 30 years of experience in the Health/ Life Sciences/Healthcare sectors in both the academic and private sectors. In addition he is also the founder and served as Executive Management /Chairman of numerous other companies in the personalized medicine, diagnostic, companion diagnostic, biomarker and systems biology sectors. He has published over 250 scientific journal manuscripts, filed over 20 patents and helped raise in excess of $100M in federal grants (NIH/SBIR) and equity investments for the companies he has been associated with over the past decade. He has worked at the MRC (UK), Mayo Clinic (USA) and consulted for most major pharma companies. Dr Naylor has degrees from the University of East Anglia (BSc-Chemistry), University of Southampton (MSc-Oceanography), University of California (MS-Chemical Sciences) and University of Cambridge (PhD-Analytical Biochemistry/Chemistry) and also was a Postdoctoral Fellow at MIT in toxicology.